Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor.

Raposeiras-Roubín S, Abu-Assi E, Muñoz-Pousa I, Cespón-Fernández M, Cobas-Paz R, Caneiro-Queija B, López-Rodríguez E, Pérez-Casares L, Jamhour-Chelh K, Castiñeira-Busto M, Barreiro-Pardal C, Calvo-Iglesias F, Íñiguez-Romo A.

Thromb Res. 2019 Feb;174:51-58. doi: 10.1016/j.thromres.2018.12.014. Epub 2018 Dec 8.

PMID:
30562722
2.

Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI.

Conrotto F, Bertaina M, Raposeiras-Roubin S, Kinnaird T, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Rognoni A, Boccuzzi G, Omedè P, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores Blanco P, Garay A, Quadri G, Varbella F, Caneiro Queija B, Cobas Paz R, Cespón Fernández M, Muñoz Pousa I, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Valdés M, Cequier A, Alexopoulos D, Iñiguez-Romo A, Gaita F, Abu-Assi E, D'Ascenzo F.

Eur Heart J Acute Cardiovasc Care. 2018 Oct 1:2048872618802783. doi: 10.1177/2048872618802783. [Epub ahead of print]

PMID:
30270638
3.

Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome.

Raposeiras-Roubín S, Caneiro Queija B, D'Ascenzo F, Kinnaird T, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Quadri G, Rognoni A, Boccuzzi G, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores Blanco P, Garay A, Varbella F, Tomassini F, Cobas Paz R, Cespón Fernández M, Muñoz Pousa I, Gallo D, Morbiducci U, Domínguez-Rodríguez A, Baz-Alonso JA, Calvo-Iglesias F, Valdés M, Cequier Á, Gaita F, Alexopoulos D, Íñiguez-Romo A, Abu-Assi E.

Rev Esp Cardiol (Engl Ed). 2019 Mar;72(3):215-223. doi: 10.1016/j.rec.2018.06.004. Epub 2018 Jul 18. English, Spanish.

PMID:
30029980
4.

Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel.

Raposeiras-Roubín S, Abu-Assi E, D'Ascenzo F, Fernández-Barbeira S, Kinnaird T, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Quadri G, Rognoni A, Boccuzzi G, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores Blanco P, Garay A, Varbella F, Tommassini F, Caneiro Queija B, Cobas Paz R, Cespón Fernández M, Muñoz Pousa I, Gallo D, Morbiducci U, Domínguez-Rodríguez A, Baz-Alonso JA, Valdés M, Cequier Á, Gaita F, Alexopoulos D, Íñiguez-Romo A.

Rev Esp Cardiol (Engl Ed). 2019 Apr;72(4):298-304. doi: 10.1016/j.rec.2018.05.021. Epub 2018 Jun 25. English, Spanish.

PMID:
29954720
5.

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.

Pato Pato A, Costa Arpín E, Rodríguez Regal A, Rodríguez Constenla I, Cimas Hernando I, Muñoz Pousa I, Naya Ríos L, Lorenzo González JR, Amigo Jorrín MC, Prieto González JM.

Neurologia. 2018 May 10. pii: S0213-4853(18)30083-5. doi: 10.1016/j.nrl.2018.02.003. [Epub ahead of print] English, Spanish.

Supplemental Content

Loading ...
Support Center